|
1
|
Troiani T, Martinelli E, Napolitano S,
Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A,
Sforza V, Nappi A, et al: Increased TGF-α as a mechanism of
acquired resistance to the anti-EGFR inhibitor cetuximab through
EGFR-MET interaction and activation of MET signaling in colon
cancer cells. Clin Cancer Res. 19:6751–6765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yin H, Zhang Q, Wang X, Li T, Wan Y, Liu Y
and Zhu J: Role of paxillin in colorectal carcinoma and its
relationship to clinico-pathological features. Chin Med J.
127:423–429. 2014.
|
|
3
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shigeta K, Hayashida T, Hoshino Y,
Okabayashi K, Endo T, Ishii Y, Hasegawa H and Kitagawa Y:
Expression of epidermal growth factor receptor detected by
cetuximab indicates its efficacy to inhibit in vitro and in vivo
proliferation of colorectal cancer cells. PLoS One. 8:e663022013.
View Article : Google Scholar :
|
|
5
|
Galizia G, Lieto E, De Vita F, Orditura M,
Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab,
a chimeric human mouse anti-epidermal growth factor receptor
monoclonal antibody, in the treatment of human colorectal cancer.
Oncogene. 26:3654–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen MC, Chiang FF and Wang HM: Cetuximab
plus chemotherapy as first-line treatment for metastatic colorectal
cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese
patients. Neoplasma. 60:561–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012.PubMed/NCBI
|
|
10
|
Munshi N, Groopman JE, Gill PS and Ganju
RK: c-Src mediates mitogenic signals and associates with
cytoskeletal proteins upon vascular endothelial growth factor
stimulation in Kaposi's sarcoma cells. J Immunol. 164:1169–1174.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishibe S, Joly D, Zhu X and Cantley LG:
Phosphorylation-dependent paxillin-ERK association mediates
hepatocyte growth factor-stimulated epithelial morphogenesis. Mol
Cell. 12:1275–1285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sen A, O'Malley K, Wang Z, Raj GV,
Defranco DB and Hammes SR: Paxillin regulates androgen-and
epidermal growth factor-induced MAPK signaling and cell
proliferation in prostate cancer cells. J Biol Chem.
285:28787–28795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Turner CE: Paxillin interactions. J Cell
Sci. 113:4139–4140. 2000.PubMed/NCBI
|
|
14
|
Xiao LJ, Zhao EH, Zhao S, Zheng X, Zheng
HC, Takano Y and Song HR: Paxillin expression is closely linked to
the pathogenesis, progression and prognosis of gastric carcinomas.
Oncol Lett. 7:189–194. 2014.
|
|
15
|
Jun Q, Zhiwei W, Lilin M, Jing K and
Qichao N: Effects of paxillin on HCT-8 human colorectal cancer
cells. Hepatogastroenterology. 58:1951–1955. 2011.PubMed/NCBI
|
|
16
|
Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY,
Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, et al: Overexpression of
paxillin induced by miR-137 suppression promotes tumor progression
and metastasis in colorectal cancer. Carcinogenesis. 34:803–811.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu DW, Wu TC, Wu JY, Cheng YW, Chen YC,
Lee MC, Chen CY and Lee H: Phosphorylation of paxillin confers
cisplatin resistance in non-small cell lung cancer via activating
ERK-mediated Bcl-2 expression. Oncogene. 33:4385–4395. 2014.
View Article : Google Scholar
|
|
18
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar SS, Price TJ, Mohyieldin O, Borg M,
Townsend A and Hardingham JE: KRAS G13D mutation and sensitivity to
cetuximab or panitumumab in a colorectal cancer cell line model.
Gastrointest Cancer Res. 7:23–26. 2014.PubMed/NCBI
|
|
21
|
Ishibe S, Joly D, Liu ZX and Cantley LG:
Paxillin serves as an ERK-regulated scaffold for coordinating FAK
and Rac activation in epithelial morphogenesis. Mol Cell.
16:257–267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Güller MC, André J, Legrand A, Setterblad
N, Mauviel A, Verrecchia F, Daniel F and Bernuau D: c-Fos
accelerates hepatocyte conversion to a fibroblastoid phenotype
through ERK-mediated upregulation of paxillin-Serine178
phosphorylation. Mol Carcinog. 48:532–544. 2009. View Article : Google Scholar
|
|
23
|
Teranishi S, Kimura K and Nishida T: Role
of formation of an ERK-FAK-paxillin complex in migration of human
corneal epithelial cells during wound closure in vitro. Invest
Ophthalmol Vis Sci. 50:5646–5652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Çoker-Gürkan A, Arisan ED, Obakan P and
Palavan-Unsal N: Lack of functional p53 renders DENSpm-induced
autophagy and apoptosis in time dependent manner in colon cancer
cells. Amino Acids. 47:87–100. 2015. View Article : Google Scholar
|
|
25
|
Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y,
Chen W, Wang K, Li D, Jin W, et al: JNK confers 5-fluorouracil
resistance in p53-deficient and mutant p53-expressing colon cancer
cells by inducing survival autophagy. Sci Rep. 4:46942014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishikawa T, Tsuno NH, Okaji Y, Shuno Y,
Sasaki K, Hongo K, Sunami E, Kitayama J, Takahashi K and Nagawa H:
Inhibition of autophagy potentiates sulforaphane-induced apoptosis
in human colon cancer cells. Ann Surg Oncol. 17:592–602. 2010.
View Article : Google Scholar
|
|
28
|
Zhai H, Song B, Xu X, Zhu W and Ju J:
Inhibition of autophagy and tumor growth in colon cancer by
miR-502. Oncogene. 32:1570–1579. 2013. View Article : Google Scholar
|
